Add press release with primary efficacy analysis of Moderna vaccine

ljl-covid · Nov 30, 2020 · 1d877a4 · 1d877a4
1 parent 0070114
commit 1d877a4
Showing 1 changed file with 1 addition and 0 deletions.
diff --git a/README.md b/README.md
@@ -393,6 +393,7 @@ There is mixed advice on the use of masks by the general public, and the advice
 * [Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study](https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy), announces the company in a press release claiming a first interim analysis of 95 COVID cases showed an efficacy of 94.5% for their mRNA-1273 vaccine, and severe cases only in the control arm, during their [COVE Phase 3 trial](https://www.modernatx.com/cove-study)
 * [Oxford University](https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine) and [AstraZeneca](https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html) both issue press releases on interim efficacy assessment of their ChAdOx1 nCoV-2019 vaccine, showing overall 70% efficacy but divided into 62% for a group that received two full doses, and 90% for a group receiving a half dose followed by a full-dose booster, and Derek Lowe discusses these results and the methodological differences compared to Pfizer and Moderna in [Oxford/AZ Vaccine Efficacy Data](https://blogs.sciencemag.org/pipeline/archives/2020/11/23/oxford-az-vaccine-efficacy-data)
 * [Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose](https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), as announced by Gamaleya in a press release, where it was also specified that no significant adverse reactions have occurred; the international price for this vaccine was stated as being below $10
+* [Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study) in a press release where efficacy is put at 94.1%, with 100% efficacy against "severe" cases, after 196 COVID cases have developed within the trial participants, and after more than two months of follow-up
 
 
 ## API and feeds